🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Pharvaris Netherlands B.V.
Phase 3
48
Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton
2025-10-15
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
188
Sutton, London
2025-10-15
Recruiting
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
NCT07260669Endometriosis
Gesynta Pharma AB
Phase 2
190
Bradford, Bristol, Corby, Coventry, London, Northwood, Norwich, Orpington
2025-10-15
Not yet open
Assessing Patient Preference for Infusion Systems
NCT07189013Primary Immunodeficiencies (PID), Secondary Immunodeficiencies (SID)
KORU Medical Systems, Inc.
Not applicable
52
London
2025-10-15
Recruiting
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727Alzheimer's Disease
Alnylam Pharmaceuticals
Phase 1
50
Glasgow, London, Sheffield, Southampton
2025-10-15
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.
Phase 2
100
Headington, London, Manchester
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Recruiting
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
NCT07115004Von Willebrand Disease (VWD)
Vega Therapeutics, Inc
Phase 3
60
London
2025-10-15
Active, closed
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254Angelman Syndrome
Ultragenyx Pharmaceutical Inc
Phase 2
60
London, Oxford
2025-10-13
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234Geographic Atrophy
Sanofi
Phase 1/2
104
London
2025-10-09
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals
Phase 2
104
Liverpool, London
2025-10-09
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
Oxford, Bath, Wolverhampton, London
2025-10-08
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
Merck Sharp & Dohme LLC
Phase 2
182
Harlow, Leeds, London
2025-10-08
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488Multiple Myeloma
Celgene
Phase 1/2
62
London, Manchester
2025-10-07
Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT07023614Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Phase 2
165
London, Glasgow, Oxford
2025-10-06
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport
2025-10-03
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Cambridge, London, Edinburgh, Liverpool
2025-10-03
Recruiting
CALM Study: Can A Prebiotic Fibre bLend Improve Stress, Mood, and Anxiety?
NCT07201909Stress
Myota GmbH
Not applicable
156
London
2025-10-02
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S
Phase 3
1,280
London, Manchester, Bellshill, Birmingham, Cardiff, Liverpool
2025-10-02
Recruiting
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161Metastatic Prostate Cancer
AstraZeneca
Phase 1/2
283
Cambridge, London, Plymouth, Sutton
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Cambridge, Edinburgh, Greater Manchester, London, Rainhill, Sheffield, Stockport
2025-10-01
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908NSCLC Stage IV
ImmunityBio, Inc.
Phase 3
507
Belfast, Truro, Bodelwyddan, Cardiff, London, Southampton, Edinburgh, Guildford
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
London
2025-10-01
By invitation
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT07204938Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.
Phase 3
145
Bristol, Cambridge, Frimley, Hampstead, London, Plymouth
2025-10-01
Recruiting
AI-Driven Early Detection of Skin Cancer
NCT07144306Skin Cancer Melanoma
Nuvana Healthcare LTD
Observational
100
London
2025-10-01
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
Bristol-Myers Squibb
Phase 2/3
470
Glasgow, London, Sheffield
2025-09-30
Recruiting
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT07161544Stargardt Disease
AAVantgarde Bio Srl
Phase 1/2
75
London
2025-09-29
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417Ulcerative Colitis
Alfasigma S.p.A.
Phase 3
80
Bristol, Glasgow, Liverpool, London, Newcastle, Sheffield
2025-09-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer
Phase 3
680
London, Manchester
2025-09-29
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
London, Liverpool, Oxford, Cambridge
2025-09-29
Recruiting
A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma
NCT07009236Glaucoma
iSTAR Medical
Not applicable
60
Colchester, Grimsby, Liverpool, London
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Blackburn, Cardiff, Plymouth, Torquay, London, Maidstone, Edinburgh, Manchester
2025-09-28
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.
Phase 3
1,300
London
2025-09-26
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
London, Newcastle upon Tyne
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
Rhythm Pharmaceuticals, Inc.
Phase 3
39
London, Birmingham, Hull
2025-09-23
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
3,040
London, Southampton, Salford, Bristol, High Wycombe, Kirkcaldy
2025-09-22
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
Cambridge, Leicester, London, Salford
2025-09-19
Recruiting
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
55
Bradford, Wakefield, Leeds, London
2025-09-18
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Milton Keynes, London, Southampton, Salford, Chertsey, Reading, Rotherham
2025-09-17
Recruiting
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
NCT07176689Desmoid Tumor, Aggressive Fibromatosis
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 4
50
Cambridge, London, Manchester
2025-09-17
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Phase 3
160
Nottingham, London, Salford
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Antrim, Bath, Birmingham, Leeds, London, Londonderry, Luton, Preston
2025-09-13
By invitation
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
NCT06549400Myotonic Dystrophy
Lupin Ltd.
Phase 3
176
London
2025-09-12
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Truro, London, Belfast, Manchester, Nottingham
2025-09-11
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Cottingham, London, Southampton, Stevenage, Surrey
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
European Real-World Registry for Use of the Ion Endoluminal System
NCT06923774Pulmonary Nodule, Lung Cancer
Intuitive Surgical
Observational
1,200
London, Manchester
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne
2025-09-08
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
NCT07136467Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
NCT07028827Myopia
Ocus Innovation Ireland Limited
Phase 3
234
Belfast, Birmingham, London
2025-09-01
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
NCT07038824Duchenne Muscular Dystrophy (DMD)
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Oxford
2025-08-30
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Guildford, Cambridge, Cardiff, London, Southampton
2025-08-28
Recruiting
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
NCT07200908Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.
Phase 3
172
Birmingham, London, Manchester, Cottingham
2025-08-27
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
Relay Therapeutics, Inc.
Phase 3
540
Bath, Cardiff, London, Manchester, Swindon, Truro
2025-08-26
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07160244Healthy
Pfizer
Phase 3
6,000
Bristol, London, Truro, Southampton, Manchester, Oxford, Shropshire, Leeds
2025-08-25
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx
Phase 3
218
Salford, Leeds, London
2025-08-22
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
London, Manchester
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
218
London
2025-08-19
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
London
2025-08-18
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
London, Newcastle upon Tyne
2025-08-18
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-08-14
Recruiting
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709Alzheimer's Disease
GlaxoSmithKline
Phase 2
220
Birmingham, Bristol, London
2025-08-14
Recruiting
Phase 1 Study of ADX-626 in Healthy Participants
NCT07081503Healthy Adult Participants
ADARx Pharmaceuticals, Inc.
Phase 1
44
London
2025-08-12
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
Sanofi
Phase 3
192
London
2025-08-12
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
NCT07099898Neoplasms, Lung
GlaxoSmithKline
Phase 3
420
London, Portsmouth, Truro
2025-08-11
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
London, Manchester, Oxford, Bath, Sheffield
2025-08-11
Recruiting
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT06449001Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
Alexion Pharmaceuticals, Inc.
Phase 3
6
Leeds, London
2025-08-11
Recruiting
Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma
NCT07189806Asthma (Diagnosis)
Hvivo
Observational
250
London
2025-08-08
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Sickle Cell Disease Vaso-occlusive Crisis
CSL Behring
Phase 2
70
London
2025-08-07
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Cambridge, Cardiff, Dundee, London
2025-08-07
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading
2025-08-06
Active, closed
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
NCT07142811Viral Hepatitis
Vir Biotechnology, Inc.
Phase 2
100
London, Manchester, Nottingham
2025-08-05
Active, closed
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
NCT06876363X-Linked Chronic Granulomatous Disease
Ensoma
Phase 1/2
15
London
2025-08-05
Recruiting
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
NCT07139743Progressive Multiple Sclerosis
Autolus Limited
Phase 1
18
Cambridge, Edinburgh, London, Sheffield
2025-08-04
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
AstraZeneca
Phase 3
800
Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro
2025-08-01
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
Pfizer
Phase 3
208
Brighton, London
2025-07-31
Active, closed
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd
Observational
50
Westcliff-on-Sea, Birmingham, Cambridge, Coventry, London, Preston, Southampton
2025-07-31
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1
434
London, Sutton
2025-07-31
Recruiting
Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
NCT07104955Cancer (Solid Tumors), Sarcoma
Salutare Group Ltd.
Not applicable
40
London
2025-07-31
Recruiting
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
NCT07127172Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
Neuralink Corp
Not applicable
7
London, Newcastle upon Tyne
2025-07-31
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
BioMarin Pharmaceutical
Phase 2
60
London
2025-07-30
Active, closed
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT07128550Viral Hepatitis
Vir Biotechnology, Inc.
Phase 3
150
London, Manchester, Nottingham
2025-07-30
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
Gloucester, London, Southampton, Sunderland, Belfast, Frimley, Manchester
2025-07-30
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
NCT06328608Fabry Disease
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
London
2025-07-29
Active, closed
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
NCT06878365Type 1 Interferonopathies
Boehringer Ingelheim
Phase 1
16
Edinburgh, London
2025-07-29
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
Celgene
Phase 3
400
Cringleford, Canterbury, London, Manchester
2025-07-28
Recruiting
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905Hemophilia B
CSL Behring
Phase 3
20
London, Oxford
2025-07-28
Recruiting
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
London, Southampton
2025-07-25
Rows per page Showing 301–400 of 2005
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=4

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.